company background image
M7T

Mach7 TechnologiesASX:M7T Stock Report

Market Cap

AU$227.8m

7D

4.7%

1Y

-4.3%

Updated

18 Oct, 2021

Data

Company Financials +
M7T fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

M7T Overview

Mach7 Technologies Limited provides enterprise imaging data sharing, storage, and interoperability for healthcare enterprises worldwide.

Rewards

Earnings are forecast to grow 93.54% per year

Risk Analysis

No risks detected for M7T from our risk checks.

Mach7 Technologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mach7 Technologies
Historical stock prices
Current Share PriceAU$0.99
52 Week HighAU$0.88
52 Week LowAU$1.59
Beta1.2
1 Month Change-3.40%
3 Month Change9.95%
1 Year Change-4.33%
3 Year Change452.78%
5 Year Change121.11%
Change since IPO57.94%

Recent News & Updates

Jul 27
Mach7 Technologies Limited's (ASX:M7T) Analyst Just Slashed This Year's Estimates

Mach7 Technologies Limited's (ASX:M7T) Analyst Just Slashed This Year's Estimates

Market forces rained on the parade of Mach7 Technologies Limited ( ASX:M7T ) shareholders today, when the covering...

Feb 19
Upgrade: The Latest Revenue Forecasts For Mach7 Technologies Limited (ASX:M7T)

Upgrade: The Latest Revenue Forecasts For Mach7 Technologies Limited (ASX:M7T)

Mach7 Technologies Limited ( ASX:M7T ) shareholders will have a reason to smile today, with the covering analyst making...

Shareholder Returns

M7TAU Healthcare ServicesAU Market
7D4.7%0.2%0.9%
1Y-4.3%46.7%20.2%

Return vs Industry: M7T underperformed the Australian Healthcare Services industry which returned 46.7% over the past year.

Return vs Market: M7T underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is M7T's price volatile compared to industry and market?
M7T volatility
M7T Beta1.2
Industry Beta0.49
Market Beta1

Stable Share Price: M7T is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: M7T's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007n/aMike Lampronhttps://www.mach7t.com

Mach7 Technologies Limited provides enterprise imaging data sharing, storage, and interoperability for healthcare enterprises worldwide. It operates through two segments, Sale of Software Licenses and Rendering of Professional Services. The Company offers enterprise diagnostic viewing solutions that include eUnity Enterprise Viewer and eUnity Diagnostic Viewer.

Mach7 Technologies Fundamentals Summary

How do Mach7 Technologies's earnings and revenue compare to its market cap?
M7T fundamental statistics
Market CapAU$227.79m
Earnings (TTM)-AU$9.36m
Revenue (TTM)AU$19.25m

12.3x

P/S Ratio

-25.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
M7T income statement (TTM)
RevenueAU$19.25m
Cost of RevenueAU$16.42m
Gross ProfitAU$2.83m
ExpensesAU$12.19m
Earnings-AU$9.36m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.039
Gross Margin14.71%
Net Profit Margin-48.61%
Debt/Equity Ratio0%

How did M7T perform over the long term?

See historical performance and comparison

Valuation

Is Mach7 Technologies undervalued compared to its fair value and its price relative to the market?

4.08x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: M7T (A$1) is trading above our estimate of fair value (A$0.01)

Significantly Below Fair Value: M7T is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: M7T is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.

PE vs Market: M7T is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate M7T's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: M7T is overvalued based on its PB Ratio (4.1x) compared to the AU Healthcare Services industry average (3.8x).


Future Growth

How is Mach7 Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

93.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: M7T is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: M7T is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: M7T's is expected to become profitable in the next 3 years.

Revenue vs Market: M7T's revenue (19.2% per year) is forecast to grow faster than the Australian market (5.5% per year).

High Growth Revenue: M7T's revenue (19.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: M7T's Return on Equity is forecast to be low in 3 years time (7.5%).


Past Performance

How has Mach7 Technologies performed over the past 5 years?

28.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: M7T is currently unprofitable.

Growing Profit Margin: M7T is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: M7T is unprofitable, but has reduced losses over the past 5 years at a rate of 28.7% per year.

Accelerating Growth: Unable to compare M7T's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: M7T is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).


Return on Equity

High ROE: M7T has a negative Return on Equity (-16.16%), as it is currently unprofitable.


Financial Health

How is Mach7 Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: M7T's short term assets (A$24.4M) exceed its short term liabilities (A$7.5M).

Long Term Liabilities: M7T's short term assets (A$24.4M) exceed its long term liabilities (A$11.6M).


Debt to Equity History and Analysis

Debt Level: M7T is debt free.

Reducing Debt: M7T has no debt compared to 5 years ago when its debt to equity ratio was 12.1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable M7T has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: M7T is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 42.9% per year.


Dividend

What is Mach7 Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate M7T's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate M7T's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if M7T's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if M7T's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of M7T's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Mike Lampron

2.58yrs

Tenure

AU$633,318

Compensation

Mr. Michael Lampron, also known as Mike, serves as Managing Director and Director of Mach7 Technologies Limited since June 24, 2019 and also serves as Chief Executive Officer. With over 20 years ofexperie...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD470.06K) is about average for companies of similar size in the Australian market ($USD556.28K).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: M7T's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: M7T's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: M7T insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Mach7 Technologies Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Mach7 Technologies Limited
  • Ticker: M7T
  • Exchange: ASX
  • Founded: 2007
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$227.795m
  • Shares outstanding: 237.29m
  • Website: https://www.mach7t.com

Number of Employees


Location

  • Mach7 Technologies Limited
  • 120 Kimball Avenue
  • Suite 210
  • South Burlington
  • Vermont
  • 5403
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 07:04
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.